甘露聚糖肽合并化/放疗治疗恶性肿瘤的临床研究  

A Clinical Study of Mannan Peptide Combined with Chemotherapy/Radiotherapy in the Treatment of Malignant Tumor

作　　者：安丰田[1] 牟相成 朱文静[1] 

机构地区：[1]青岛市市立医院药剂科,山东青岛266000 [2]东营市广饶县中医院影像科,山东东营257300

出　　处：《药物生物技术》2017年第3期236-238,共3页Pharmaceutical Biotechnology

摘　　要：评价甘露聚糖肽合并化、放疗治疗肿瘤患者的疗效和安全性,同时观察甘露聚糖肽对患者免疫功能的影响。对100例恶性肿瘤患者,随机分为化学治疗组(化疗加甘露聚糖肽)和对照组(化疗)及放射治疗组(放疗加甘露聚糖肽)和对照组(放疗),分别对患者的治疗有效率、外周血CD3+、CD4+、CD8+、CD4+/CD8+、淋巴细胞转化率(LTT)、外周血白细胞(WBC)、放/化疗不良反应等指标进行比较。结果:(1)近期疗效:化疗、放疗治疗组有效率分别为68%,60%,对照组有效率分别为40%,32%,治疗组和对照组有效率差异有显著性(P<0.01)。(2)与对照组相比,化疗、放疗治疗组T细胞亚群CD3+、CD4+、CD4+/CD8+及LTT均明显升高,CD8+降低,其中化学治疗组与对照组相比CD3+、CD4+升高更明显,差异有显著性(P<0.01),放射治疗组与对照组相比CD8+略有降低,差异无显著性(P>0.05)。其余各项检测指标,治疗组与对照组相比,均存在明显的差异(P<0.05)。(3)外周血常规:治疗组外周血WBC下降病例均少于对照组,且WBC下降程度较轻,化疗、放疗治疗组与相应对照组比较差异有显著性(P<0.05)。(4)不良反应:与对照组相比,化疗、放疗治疗组发生恶心,呕吐、体重下降的病例减少,发热病例增多。甘露聚糖肽合并化、放疗可以提高恶性肿瘤的临床疗效,并提高患者的免疫功能。To evaluate the efficacy and safety of mannan peptide combined with che-motherapy/radiotherapy in the treatment of cancer patients,while monitoring the impact on immune function in patients. 100 cases of malignant tumor were randomly divided into chemotherapy group （ chemotherapy plus mannatide ）, control group （ chemotherapy alone ）, radiotherapy group （ radiotherapy plus mannatide） and control group （ radiotherapy alone）. Treatment efficiency, as well as CD3^＋ , CD4^＋ , CD8^＋ , CD4^＋/CD8^＋ , lympho- cyte transformation rate （LTT） ,white blood cell （WBC） in peripheral blood and adverse reactions were compared. ：the short-term efficacy of chemotherapy, radiotherapy treatment group was 68% ,60% , while the corresponding control group was 40% , 32% ;there was significant difference between the treatment groups and the control groups （P 〈 0.01 ）. Compared with the control groups, T cell subsets CD3^＋ ,CD4^＋ ,CIM^＋/CD8^＋and LTT were significantly increased in chemotherapy treatment group and radiotherapy treat- ment group, whlie CD8^＋ decreased slightly, and the increased degree of CD3 ^＋ and CD4 ^＋ in the chemotherapy group was significantly higher than that in the control group （P 〈 0.01 ）. There was no significant difference in CD8 ~ between the radiotherapy group and the control group （ P 〉 0.05 ）. The other indicators between the two treatment groups and control groups were significantly different （ P 〈 0.05 ）. The descending rate of peripheral blood serum WBC in treatment groups were less than that of the control groups and there were significant difference （ P 〈 0.05 ）. Compared with the control groups, the number of patients performing adverse reaction including nausea,vomiting and weight loss were less than those in the control groups, while the fever patients were more. Mannan peptide combined with chemotherapy/radiotherapy treatment could improve the clinical efficacy of malignant tumor treatment,impro- ving the immune function

关 键 词：恶性肿瘤 化学治疗 放射治疗 甘露聚糖肽 疗效 临床研究 

分 类 号：R730.53[医药卫生—肿瘤]